Why the Bionomics share price crashed 37.5% lower today

The Bionomics Ltd (ASX:BNO) share price has crashed 37.5% lower today following the release of another disappointing study result…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One of the worst performers on the Australian share market on Wednesday has been the Bionomics Ltd (ASX: BNO) share price.

In morning trade the biopharmaceutical company's shares are down a massive 37.5% to a multi-year low of 3.5 cents.

This latest decline means that the Bionomics share price has now lost close to 94% of its value over the last 12 months.

Why is the Bionomics share price down 37% today?

Investors have been heading to the exits this morning after another disappointing study result for its BNC210 product candidate.

This morning the company announced the top line results of an exploratory trial of BNC210 for the treatment of agitation in elderly patients in a hospital setting.

According to the release, the results of the trial indicated that BNC210 treatment did not differentiate from placebo on the primary and secondary efficacy end points.

A comparison of the mean peak daily Pittsburgh Agitation Scale scores (observations of aberrant vocalisation, motor agitation, aggressiveness and resisting care) showed a gradual improvement for both BNC210 and placebo over the five-day treatment period, but without evidence of a treatment effect.

Professor Paul Rolan, Bionomics consultant chief medical officer, said: "Whilst the results of the trial do not support further development of BNC210 for treatment of agitation, given BNC210's consistent safety profile and the demonstration by pharmacometric exposure-response modelling of its potential to treat post-traumatic stress disorder, we remain confident in pursuing PTSD, provided that we can achieve the blood exposure levels predicted by the modelling analysis."

The company now intends to push ahead with a single ascending dose study in healthy volunteers to demonstrate that blood levels of BNC210 believed to be necessary to meet the primary endpoints for effectiveness in treating PTSD in any further trial are achievable using the new solid dose formulation.

The cost of this study is estimated to be $300,000 and results are anticipated to be available early in the fourth quarter of the calendar year.

After which, Dr Errol De Souza, Executive Chairman of Bionomics, revealed that Bionomics intends to proceed with the further formulation development and preparation for a second Phase 2 trial if "the proposed study with the solid dose formulation confirms that the required blood levels are achievable, and the FDA guidance supports a second Phase 2 trial of BNC210 in PTSD."

Elsewhere in the industry today, the CSL Limited (ASX: CSL) share price has pushed higher and the Mayne Pharma Group Ltd (ASX: MYX) share price is trading 1% lower at a multi-year low of 47.5 cents.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Fallers

Bored man sitting at his desk with his laptop.
Share Fallers

Why Catalyst Metals, Duratec, Nufarm, and Rio Tinto shares are dropping today

These shares are ending the week in the red. But why?

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why Dexus, Mayne Pharma, Nufarm, and Treasury Wine shares are falling today

These shares are having a tough session on Thursday. But why?

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why James Hardie, Mayne Pharma, Nufarm, and Resimac shares are falling today

These shares are having a tough time on hump day. But why?

Read more »

A male investor wearing a blue shirt looks off to the side with a miffed look on his face as the share price declines.
Share Fallers

Why Kogan, Monash IVF, OFX, and ResMed shares are falling today

Why are these shares taking a tumble today? Let's find out.

Read more »

A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash
Share Fallers

Why Appen, DroneShield, Gentrack, and New Hope shares are dropping today

These shares are starting the week in the red. But why?

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Dexus, Dusk, Fletcher Building, and Paladin Energy shares are falling today

These shares are ending the week in the red. But why?

Read more »

Couple look at a bottle of wine while trying to decide what to buy.
Consumer Staples & Discretionary Shares

Treasury Wine shares: Buy, hold, or sell? Here's Macquarie's take

What is Macquarie forecasting for Treasury Wine shares amid the CEO’s unexpected exit?

Read more »

A man sits in despair at his computer with his hands either side of his head, staring into the screen with a pained and anguished look on his face, in a home office setting.
Share Fallers

Why Newmont, NRW, Peet, and Treasury Wine shares are dropping today

Let's find out why investors are selling down these shares on Thursday.

Read more »